IRAK

ND-2158 is a competitive inhibitor of IRAK4, exhibiting a Ki value of 1.3 nM. This compound effectively suppresses LPS-induced TNF production in human white blood cells and demonstrates therapeutic potential by alleviating collagen-induced arthritis and preventing gout formation in mouse models. Additionally, ND-2158 shows antitumor activity in vivo, making it a valuable tool for research in inflammation and cancer biology.

PROTAC IRAK4 Degrader-10 is a potent IRAK4 degrader that utilizes a Cereblon ligand to initiate targeted protein degradation. It demonstrates remarkable biological activity, achieving a maximum degradation of 95.94% with a DC50 value of 7.68 nM in HEK293 cells. This compound is essential for research applications focused on inflammatory signaling pathways and therapeutic strategies targeting IRAK4.

PROTAC IRAK4 Degrader-6 is a Cereblon-based PROTAC designed to selectively degrade interleukin-1 receptor-associated kinase 4 (IRAK4). This compound targets IRAK4 for ubiquitination and subsequent proteasomal degradation, effectively modulating inflammatory signaling pathways. It is utilized in research applications focused on understanding the role of IRAK4 in immune responses and developing novel therapeutic strategies for inflammatory diseases.

IRAK4-IN-11 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), demonstrating a potent inhibition profile with an IC50 of 0.008 µM. This compound effectively suppresses phosphorylated IRAK4 with an IC50 of 0.19 µM, making it a valuable tool for studying the IL-1 signaling pathway. IRAK4-IN-11 is suitable for research applications focused on inflammation, immune response, and related therapeutic areas.

IRAK4-IN-19 is a potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), with an IC50 value of 4.3 nM. This compound effectively inhibits lipopolysaccharide (LPS)-induced IL-23 production in THP-1 and dendritic cells, demonstrating its ability to influence inflammatory pathways. IRAK4-IN-19 is valuable for research focused on arthritis and other inflammatory diseases, as it has shown efficacy in preventing the development of arthritis in animal models.

HG-12-6 is a type II inhibitor of IRAK4, exhibiting preferential binding to unphosphorylated inactive IRAK4 with an IC50 of 165 nM. This compound effectively modulates IRAK4 activity, making it a valuable tool for studying its role in autoimmunity and inflammation. Researchers can utilize HG-12-6 to investigate pathways associated with immune responses and inflammatory disorders.

IRAK4-IN-25 is a potent inhibitor of IRAK4, with an IC50 of 7.3 nM, demonstrating significant oral bioavailability and low clearance (Cl=12 mL/min/kg). This compound effectively inhibits the production of pro-inflammatory cytokines, making it a valuable tool for studying inflammatory and autoimmune disorders. Its in vitro safety and ADME profiles further support its potential applications in research aimed at understanding immune response modulation.

IRAK4 ligand-14 is a selective ligand for the interleukin-1 receptor-associated kinase 4 (IRAK4). This compound can facilitate the synthesis of proteolysis-targeting chimeras (PROTACs), including APH02174. Its application in research primarily focuses on elucidating the role of IRAK4 in immune signaling pathways and developing innovative therapeutic strategies targeting IRAK4-related diseases.

IRAK4-IN-24 is a potent inhibitor of IRAK4, a key kinase involved in the signaling pathways of inflammatory responses. This compound demonstrates significant biological activity, particularly in models of inflammatory and autoimmune disorders. IRAK4-IN-24 facilitates research into the modulation of immune responses and provides insights into potential therapeutic strategies targeting IRAK4 in various disease contexts.

IRAK4-IN-26 is a potent inhibitor of IRAK4 with an IC50 of 6.2 nM. This compound exhibits an oral bioavailability of 21%, making it suitable for in vivo studies. IRAK4-IN-26 is valuable for research into inflammatory and autoimmune disorders, facilitating the exploration of therapeutic strategies targeting IRAK4 signaling pathways.

BMS-978299 is a selective inhibitor of IRAK4, a critical kinase in the Toll-like receptor (TLR) signaling pathway. This compound demonstrates potent activity in modulating immune response and inflammation, making it a valuable tool for investigating immune disorders and related therapeutic interventions. Researchers can utilize BMS-978299 to further understand the role of IRAK4 in various pathophysiological conditions and to explore potential treatment strategies for immune-related diseases.

IRAK4-IN-34 is a potent and selective inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 of 0.73 nM. This compound demonstrates significant selectivity against hERG and other kinase targets. With favorable pharmacokinetic properties for in vivo applications, IRAK4-IN-34 is valuable for research into inflammatory diseases and related pathways.

ND-2110 is a selective inhibitor of IRAK4, exhibiting a binding affinity with a Ki of 7.5 nM. It effectively targets the ATP binding site of IRAK4 and demonstrates significant biological activity in activated B cell-like (ABC) subtype diffuse large B cell lymphoma (DLBCL) cell lines harboring MYD88 L265P mutations. ND-2110 has been shown to inhibit LPS-induced TNF production and demonstrates therapeutic potential in mouse models of collagen-induced arthritis and gout.

HPK1-IN-7 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1, MAP4K1) with an IC50 of 2.6 nM, demonstrating excellent selectivity among kinases. It exhibits some selectivity against IRAK4 and GLK, with IC50 values of 59 nM and 140 nM, respectively. This compound has shown significant efficacy in the MC38 syngeneic tumor model, particularly when used in combination with anti-PD1 therapy, highlighting its potential in immuno-oncology research.

PF-05387252 is a potent and selective inhibitor of IRAK4, effectively targeting endogenous Toll-like receptor (TLR) signaling pathways. This compound exhibits significant anti-inflammatory activity in experimental models, suggesting potential therapeutic applications in conditions such as psoriasis. While PF-05387252 has demonstrated efficacy in reducing inflammation in animal studies, its effectiveness in clinical settings for psoriasis has yet to be established.

IRAK4-IN-29 is a selective inhibitor of the interleukin-1 receptor-associated kinase 4 (IRAK4), demonstrating low nanomolar activity. This compound effectively disrupts TLR-mediated signaling pathways and exhibits significant inhibition of cytokine production in response to LPS and R848 stimulation. In vivo studies reveal that IRAK4-IN-29 can suppress LPS-induced TNFα, mirroring the phenotype observed in IRAK4 gene-deficient mice. Furthermore, IRAK4-IN-29 possesses favorable medicinal chemistry characteristics, including microsomal stability and solubility, indicating its potential for clinical applications in inflammatory diseases.

3,9-Dimethyl-3,9-diazaspiro[5.5]undecane is a rigid linker designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras). This compound facilitates targeted protein degradation, exemplified by its application in creating potent IRAK4 PROTAC degraders, such as FIP22, which demonstrate efficacy in conditions like atopic dermatitis. Its structural characteristics enhance the stability and specificity of PROTAC development, making it a valuable tool in chemical biology research.

PROTAC IRAK4 ligand-1 is a synthetic ligand specifically designed to target interleukin-1 receptor-associated kinase 4 (IRAK4). This compound plays a critical role in the development of PROTAC IRAK4 degrader-1, facilitating targeted protein degradation. Its primary applications include cancer research and studies investigating inflammatory pathways, making it a valuable tool for researchers exploring IRAK4-related signaling mechanisms.

PROTAC IRAK4 ligand-3 is a PROTAC ligand that selectively targets IRAK4, an integral component of the Toll-like receptor signaling pathway. This compound facilitates the targeted degradation of IRAK4, thereby influencing key signaling cascades involved in inflammation and cancer. It is valuable for research applications focusing on cancer therapies and the modulation of inflammatory responses.

IRAK4 ligand-12 is a ligand for interleukin-1 receptor-associated kinase 4 (IRAK4), designed for use in PROTAC (proteolysis targeting chimeras) applications. This compound plays a critical role in the selective degradation of IRAK4, thus enabling the modulation of immune response pathways. It is particularly useful in research focused on inflammation and cancer, facilitating studies on targeted protein degradation strategies. IRAK4 ligand-12 can also be utilized in the synthesis of KTX-951, contributing to advancements in therapeutic development.

PROTAC IRAK4 ligand-5 is a ligand designed for use in proteolysis targeting chimera (PROTAC) applications, specifically targeting IRAK4. This compound plays a crucial role in the synthesis of KT-413, facilitating the degradation of IRAK4 to modulate immune responses. It is of particular interest for research in inflammatory diseases and therapeutic development involving targeted protein degradation.

E3 ligase Ligand 38 functions as an E3 ligase ligand, facilitating the development of targeted protein degraders. It is notably utilized in the synthesis of PROTAC IRAK4 degrader-12, contributing to innovative strategies in degrading specific proteins. This compound is essential for research applications focused on protein homeostasis and the modulation of intracellular signaling pathways.

Thalidomide-NH-C2-azaspiro[3.5]nonane hydrochloride serves as a crucial intermediate in the synthesis of IRAK degraders. Its structural properties facilitate the development of compounds that modulate immune responses by targeting IRAK proteins. This reagent is valuable for researchers focusing on therapeutic applications in inflammatory diseases and immune regulation.

E3 Ligase Ligand-linker Conjugate 226 is a synthetic conjugate utilized in the development of PROTACs targeting E3 ligases. This compound facilitates the synthesis of PROTAC IRAK3 degrader-2, possessing significant anti-tumor activity. It serves as a key tool in research applications focused on targeted protein degradation and therapeutic strategies for oncological diseases.

CRBN Ligand-Linker Conjugate 2 is an E3 ligand-linker conjugate designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates targeted degradation of specific proteins by harnessing the ubiquitin-proteasome system. It has been utilized in the development of FIP22, a highly selective IRAK4 PROTAC degrader, which demonstrates potential therapeutic activity against atopic dermatitis. Researchers can leverage this conjugate for advancements in targeted protein degradation strategies.

E3 Ligase Ligand-linker Conjugate 125 is a specialized conjugate designed to engage E3 ligases for targeted protein degradation. This reagent facilitates the synthesis of PROTAC IRAK4 degrader-12, enabling selective degradation of IRAK4, which is implicated in various signaling pathways and inflammatory processes. It serves as a valuable tool in chemical biology and therapeutic research, particularly in the study of targeted protein modulation and novel drug development strategies.

AM-Imidazole-PA-Boc is a versatile PROTAC linker characterized by its alkyl chain structure. It plays a critical role in the design and synthesis of PROTAC IRAK4 degrader-1, facilitating targeted protein degradation. This compound is essential for researchers exploring the therapeutic potential of targeted protein degradation in various signaling pathways and disease models.

PSP-0119 is a highly selective PROTAC degrader targeting IRAK4, demonstrating an IC50 of 2.83 nM. This compound effectively inhibits IRAK4 kinase activity, NF-κB signaling, and IL-1β-induced IRAK4 phosphorylation. Notably, PSP-0119 induces degradation of IRAK4 specifically in FLT3-mutant acute myeloid leukemia (AML) cell lines while sparing FLT3-wild-type AML cells and normal bone marrow. It serves as a valuable tool for research into the mechanisms underlying AML, particularly in targeting aberrant IRAK4 activity.